Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Department of Gastroenterology, Xiangya Third Hospital, Central South University, Changsha 410013, Hunan Province, China.
Biosci Rep. 2018 Sep 13;38(5). doi: 10.1042/BSR20180479. Print 2018 Oct 31.
Chromosome 14 ORF 166 (C14orf166), a protein involved in the regulation of RNA transcription and translation, has been reported to possess the potency to promote tumorigenesis; however, the role of C14orf166 in non-small-cell lung cancer (NSCLC) remains unknown. The purpose of the present study was to assess C14orf166 expression and its clinical significance in NSCLC. Immunohistochemical staining, quantitative real-time PCR (qRT-PCR), and Western blotting were used to detect the C14orf166 protein and mRNA expression levels in NSCLC tissues compared with adjacent normal tissues, as well as in NSCLC cells lines compared with normal human bronchial epithelial cells (HBE). Then, the correlations between the C14orf166 expression levels and the clinicopathological features of NSCLC were analyzed. Additionally, the Cox proportional hazard model was used to evaluate the prognostic significance of C14orf166. We found that C14orf166 expression increased in carcinoma tissues compared with their adjacent normal tissues at the protein (<0.001) and mRNA levels (<0.001). High expression of C14orf166 was significantly associated with the T stage (=0.006), lymph node metastasis (=0.001), advanced TNM stage (<0.001), and chemotherapy (<0.001). Moreover, according to the survival analysis, patients with overexpressed C14orf166 were inclined to experience a shorter overall survival and disease-free survival time (<0.001). Multivariate COX analysis implied that C14orf166 was an independent prognostic biomarker. Taken together, our findings indicate that the overexpression of C14orf166 may contribute to the disease progression of NSCLC, represent a novel prognostic predictor and help high-risk patients make better decisions for subsequent therapy.
染色体 14 开放阅读框 166（C14orf166）是一种参与 RNA 转录和翻译调控的蛋白质，据报道其具有促进肿瘤发生的能力；然而，C14orf166 在非小细胞肺癌（NSCLC）中的作用尚不清楚。本研究旨在评估 C14orf166 在 NSCLC 中的表达及其临床意义。免疫组织化学染色、实时定量 PCR（qRT-PCR）和 Western blot 用于检测 NSCLC 组织与相邻正常组织以及 NSCLC 细胞系与正常人类支气管上皮细胞（HBE）中 C14orf166 蛋白和 mRNA 的表达水平。然后，分析了 C14orf166 表达水平与 NSCLC 临床病理特征之间的相关性。此外，还使用 Cox 比例风险模型评估了 C14orf166 的预后意义。我们发现 C14orf166 在癌组织中的表达在蛋白（<0.001）和 mRNA 水平（<0.001）上均高于其相邻的正常组织。C14orf166 的高表达与 T 分期（=0.006）、淋巴结转移（=0.001）、晚期 TNM 分期（<0.001）和化疗（<0.001）显著相关。此外，根据生存分析，C14orf166 过表达的患者总体生存率和无病生存率较短（<0.001）。多因素 COX 分析表明，C14orf166 是一个独立的预后生物标志物。总之，我们的研究结果表明，C14orf166 的过表达可能促进 NSCLC 的疾病进展，代表了一种新的预后预测指标，有助于高危患者做出更好的后续治疗决策。
